Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells

Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its use is hindered by the recently expressed safety concerns. One approach for reducing SOR toxicity is to use lower doses in combination with other less toxic agents. Biochanin-A (Bio-A), a promising isoflavon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Youssef , Mohieldin M., Tolba, Mai F., Badawy, Noha N., Liu, Andrew W., El-Ahwany, Eman, Khalifa, Amani E., Zada, Suher, Abdel-Naim, Ashraf B.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4965826/
https://ncbi.nlm.nih.gov/pubmed/27470322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep30717
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados